La diversidad está en nuestro ADN

El futuro lo construyen personas como usted. En Twist, todos somos más fuertes debido a la variedad de experiencias y antecedentes laborales que los Twisters aportan a sus trabajos todos los días. A continuación, se muestran algunos de los lugares del mundo donde crecieron los empleados de Twist.
Mapa del equipo

Equipo de liderazgo

  • Dra. Emily Leproust, TwistBioscience
    Dra. Emily Leproust

    Directora ejecutiva y cofundadora de Twist

    Leer la biografía/publicaciones
    x
    Dra. Emily Leproust, TwistBioscience

    Dra. Emily Leproust

    Directora ejecutiva y cofundadora de Twist

    Como pionera en la síntesis y secuenciación de ADN de alto rendimiento, la Dra. Leproust está revolucionando los mercados para permitir el crecimiento exponencial de aplicaciones basadas en ADN que incluyen productos químicos/materiales, diagnósticos, tratamientos terapéuticos, alimentos y almacenamiento de datos digitales. En 2020, BIO le otorgó el premio Rosalind Franklin al liderazgo. Foreign Policy la nombró una de sus 100 pensadores líderes globales y Fast Company la nombró una de las personas más creativas del mundo empresarial. Antes de Twist Bioscience, ocupó puestos en ascenso en Agilent Technologies, donde diseñó la exitosa línea de productos SureSelect que redujo el coste de la secuenciación y esclareció los mecanismos responsables de docenas de enfermedades mendelianas. También desarrolló la tecnología de síntesis de bibliotecas de oligonucleótidos, donde inició y dirigió actividades de desarrollo de productos y negocios para el equipo. La Dra. Leproust diseñó y desarrolló múltiples plataformas de síntesis comerciales para agilizar la producción y fabricación de micromatrices. She serves on the Board of Directors of GeneDx and is a co-founder of Petri, an accelerator for start-ups at the forefront of engineering and biology. La Dra. Leproust ha publicado más de 30 artículos revisados por expertos, muchos sobre aplicaciones de ADN sintético, y es autora de numerosas patentes. Obtuvo su doctorado en Química Orgánica en la Universidad de Houston y su licenciatura en Química Industrial en la Escuela de Química Industrial de Lyon. 

    Publicaciones
    Structure-guided SCHEMA recombination generates diverse chimeric channelrhodopsins

    Bedbrook CN, Rice AJ, Yang KK, Ding X, Chen S, LeProust EM, Gradinaru V, Arnold FH.
    PNAS. 2017 114(13) E2624-E2633
    Polycomb repressive complex PRC1 spatially constrains the mouse embryonic stem cell genome

    Schoenfelder S, Sugar R, Dimond A, Javierre B, Armstrong H, Mifsud B, Dimitrova E, Matheson L, Tavares-Cadete F, Furlan-Magaril M, Segonds-Pichon A, Jurkowski W, Wingett SW, Tabbada K, Andrews S, Herman B, LeProust EM, Osborne CS, Koseki H, Fraser P, Luscombe NM, Elderkin S.
    Nature Genetics. 2015 47 1179–1186
    Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C

    Mifsud B, Tavares-Cadete F, Young AN, Sugar R, Schoenfelder S, Ferreira L, Wingett SW, Andrews S, Grey W, Ewels PA, Herman B, Happe S, Higgs A, LeProust EM, Follows GA, Fraser P, Luscombe NM, Osborne CS.
    Nature Genetics. 47 (6) 598-606.
    The pluripotent regulatory circuitry connecting promoters to their long-range interacting elements

    Schoenfelder S, Furlan-Magaril M, Mifsud B, Tavares-Cadete F, Sugar, R, Javierre B, Nagano T, Katsman Y, Sakthidevi M, Wingett SW, Dimitrova E, Dimond A, Edelman LB, Elderkin S, Tabbada K, Darbo E, Andrews S, Herman B, Higgs A, LeProust EM, Osborne CS, Mitchell JA, Luscombe NM, Fraser P.
    Genome Res. 2015. 25: 582-597
    Utilizing ethnic-specific differences in minor allele frequency to recategorize reported pathogenic deafness variants

    Shearer AE, Eppsteiner RW, Booth KT, Ephraim SS, Gurrola J, Simpson A, Black-Ziegelbein EA, Joshi S, Ravi H, Giuffre AC, Happe S, Hildebrand MS, Azaiez H, Bayazit YA, Erdal ME, Lopez-Escamez JA, Gazquez I, Tamayo ML, Gelvez NY, Leal GL, Jalas C, Ekstein J, Yang T, Usami S, Kahrizi K, Bazazzadegan N, Najmabadi H, Scheetz TE, Braun TA, Casavant TL, LeProust EM, Smith RJ.
    The American Journal of Human Genetics. 95 4 445-453

    Systematic Identification of Barriers to Human iPSC Generation
    Qin H, Diaz A, Blouin L, Lebbink RJ, Patena W, Tanbun P, LeProust EM, McManus MT, Song JS, Ramalho-Santos M.
    158 (2) 449–461

    A high-coverage shRNA screen identifies TMEM129 as an E3 ligase involved in ER-associated protein degradation
    van de Weijer ML, Bassik MC, Luteijn RD, Voorburg CM, Lohuis MA, Kremmer E, Hoeben RC, LeProust EM, Chen S, Hoelen H, Ressing ME, Patena W, Weissman JS, McManus MTa, Wiertz, EJa, and Lebbink RJa.
    Nat Commun. (2014) 5: 3832.

    Evidence for the biogenesis of more than 1,000 novel human microRNAs

    Friedländer MR, Lizano E, Houben AJS, Bezdan D, Báñez-Coronel M, Kudla G, Mateu-Huertas E, Kagerbauer B, González J, Chen KC, LeProust EM, Martí E, Estivill X.
    Genome biology. 2014 15:R57
    Exonic Transcription Factor Binding Directs Codon Choice and Affects Protein Evolution

    Stergachis AB, Haugen E, Shafer A, Fu W, Vernot B, Reynolds A, Raubitschek A, Ziegler S, LeProust EM, Akey JM, Stamatoyannopoulos JA.
    Science. 2013 342(6164) 1367-1372
    Advancing genetic testing for deafness with genomic technology.

    Shearer AE, Black-Ziegelbein EA, Hildebrand MS, Eppsteiner RW, Ravi H, Joshi S, Guiffre AC, Sloan CM, Happe S, Howard SD, Novak B, Deluca AP, Taylor KR, Scheetz TE, Braun TA, Casavant TL, Kimberling WJ, Leproust EM, Smith RJ.
    Journal of Medical Genetics. 2013 50(9) 627-34
    A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility.

    Bassik MC, Kampmann M, Lebbink RJ, Wang S, Hein MY, Poser I, Weibezahn J, Horlbeck MA, Chen S, Mann M, Hyman AA, Leproust EM, McManus MT, Weissman JS.
    Cell. 2013 152(4) 909-22
    Towards practical, high-capacity, low-maintenance information storage in synthesized DNA.

    Goldman N, Bertone P, Chen S, Dessimoz C, LeProust EM, Sipos B, Birney E.
    Nature. 2013 494(7435) 77-80
    Targeted genome enrichment for efficient purification of endosymbiont DNA from host DNA.

    Geniez S, Foster JM, Kumar S, Moumen B, Leproust E, Hardy O, Guadalupe M, Thomas SJ, Boone B, Hendrickson C, Bouchon D, Grève P, Slatko BE.
    Symbiosis. 2012 58 (1-3) 201-207
    Mitochondrial disease genetic diagnostics: optimized whole-exome analysis for all MitoCarta nuclear genes and the mitochondrial genome.

    Falk MJ, Pierce EA, Consugar M, Xie MH, Guadalupe M, Hardy O, Rappaport EF, Wallace DC,LeProust E, Gai X.
    Discovery Medicine. 2012 14(79) 389-99
    Pre-capture multiplexing improves efficiency and cost-effectiveness of targeted genomic enrichment.

    Shearer AE, Hildebrand MS, Ravi H, Joshi S, Guiffre AC, Novak B, Happe S, LeProust EM, Smith RJ. BMC Genomics. 2012 13 618
    Target enrichment strategies for next generation sequencing.

    Leproust E.
    Medical Laboratory Observer. 2012 44(6) 26-7
    Myofibrillar myopathy caused by a mutation in the motor domain of mouse MyHC IIb.

    Kurapati R, McKenna C, Lindqvist J, Williams D, Simon M, LeProust E, Baker J, Cheeseman M, Carroll N, Denny P, Laval S, Lochmüller H, Ochala J, Blanco G.
    Human Molecular Genetics. 2012 21(8) 1706-24
    Specific capture and whole-genome sequencing of viruses from clinical samples.

    Depledge DP, Palser AL, Watson SJ, Lai IY, Gray ER, Grant P, Kanda RK, Leproust E, Kellam P, Breuer J.
    PLoS One. 2011 6(11) e27805
    Autoantigen discovery with a synthetic human peptidome.

    Larman HB, Zhao Z, Laserson U, Li MZ, Ciccia A, Gakidis MA, Church GM, Kesari S, Leproust EM, Solimini NL, Elledge SJ.
    Nature Biotechnology. 2011 29(6) 535-41
    Efficient and cost effective population resequencing by pooling and in-solution hybridization.

    Bansal V, Tewhey R, Leproust EM, Schork NJ.
    PLoS One. 2011 6(3) e18353
    The GENCODE exome: sequencing the complete human exome.

    Coffey AJ, Kokocinski F, Calafato MS, Scott CE, Palta P, Drury E, Joyce CJ, Leproust EM, Harrow J, Hunt S, Lehesjoki AE, Turner DJ, Hubbard TJ, Palotie A.
    European Journal Human Genetics. 2011 19(7) 827-31
    Scalable gene synthesis by selective amplification of DNA pools from high-fidelity microchips.

    Kosuri S, Eroshenko N, Leproust EM, Super M, Way J, Li JB, Church GM.
    Nature Biotechnology. 2010 28(12) 1295-9
    Temporal and spatial profile of brain diffusion-weighted MRI after cardiac arrest.

    Mlynash M, Campbell DM, Leproust EM, Fischbein NJ, Bammer R, Eyngorn I, Hsia AW, Moseley M, Wijman CA.
    Stroke. 2010 41(8) 1665-72
    Synthesis of high-quality libraries of long (150mer) oligonucleotides by a novel depurination controlled process.

    LeProust EM, Peck BJ, Spirin K, McCuen HB, Moore B, Namsaraev E, Caruthers MH.
    Nucleic Acids Research. 2010 38(8) 2522-40
    Enrichment of sequencing targets from the human genome by solution hybridization.

    Tewhey R, Nakano M, Wang X, Pabón-Peña C, Novak B, Giuffre A, Lin E, Happe S, Roberts DN,LeProust EM, Topol EJ, Harismendy O, Frazer KA.
    Genome Biology. 2009 10(10) R116
    Digital RNA allelotyping reveals tissue-specific and allele-specific gene expression in human.

    Zhang K, Li JB, Gao Y, Egli D, Xie B, Deng J, Li Z, Lee JH, Aach J, Leproust EM, Eggan K, Church GM.
    Nature Methods. 2009 6(8) 613-8
    Multiplex padlock targeted sequencing reveals human hypermutable CpG variations.

    Li JB, Gao Y, Aach J, Zhang K, Kryukov GV, Xie B, Ahlford A, Yoon JK, Rosenbaum AM, Zaranek AW, LeProust E, Sunyaev SR, Church GM.
    Genome Research. 2009 19(9) 1606-15
    Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing.

    Li JB, Levanon EY, Yoon JK, Aach J, Xie B, Leproust E, Zhang K, Gao Y, Church GM.
    Science. 2009 324(5931) 1210-3
    Rapid creation and quantitative monitoring of high coverage shRNA libraries.

    Bassik MC, Lebbink RJ, Churchman LS, Ingolia NT, Patena W, LeProust EM, Schuldiner M, Weissman JS, McManus MT.
    Nature Methods. 2009 6(6) 443-5
    Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming.

    Deng J, Shoemaker R, Xie B, Gore A, LeProust EM, Antosiewicz-Bourget J, Egli D, Maherali N, Park IH, Yu J, Daley GQ, Eggan K, Hochedlinger K, Thomson J, Wang W, Gao Y, Zhang K.
    Nature Biotechnology. 2009 27(4) 353-60
    Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells.

    Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, Park IH, Xie B, Daley GQ, Church GM.
    Nature Biotechnology. 2009 27(4) 361-8
    Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing.

    Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, Brockman W, Fennell T, Giannoukos G, Fisher S, Russ C, Gabriel S, Jaffe DB, Lander ES, Nusbaum C.
    Nature Biotechnology. 2009 27(2) 182-9
    The DNA-encoded nucleosome organization of a eukaryotic genome.

    Kaplan N, Moore IK, Fondufe-Mittendorf Y, Gossett AJ, Tillo D, Field Y, LeProust EM, Hughes TR, Lieb JD, Widom J, Segal E.
    Nature. 2009 458(7236) 362-6
    Multiplex amplification of large sets of human exons.

    Porreca GJ, Zhang K, Li JB, Xie B, Austin D, Vassallo SL, LeProust EM, Peck BJ, Emig CJ, Dahl F, Gao Y, Church GM, Shendure J.
    Nature Methods. 2007 4(11) 931-6
    Production of complex nucleic acid libraries using highly parallel in situ oligonucleotide synthesis.

    Cleary MA, Kilian K, Wang Y, Bradshaw J, Cavet G, Ge W, Kulkarni A, Paddison PJ, Chang K, Sheth N, Leproust E, Coffey EM, Burchard J, McCombie WR, Linsley P, Hannon GJ.
    Nature Methods. 2004 1(3) 241-8
    Effects of atmospheric ozone on microarray data quality.

    Fare TL, Coffey EM, Dai H, He YD, Kessler DA, Kilian KA, Koch JE, LeProust E, Marton MJ, Meyer MR, Stoughton RB, Tokiwa GY, Wang Y.
    Analytical Chemistry. 2003 75(17) 4672-5
    A flexible light-directed DNA chip synthesis gated by deprotection using solution photogenerated acids.

    Gao X, LeProust E, Zhang H, Srivannavit O, Gulari E, Yu P, Nishiguchi C, Xiang Q, Zhou X.
    Nucleic Acids Research. 2001 29(22) 4744-50.
    Characterization of oligodeoxyribonucleotide synthesis on glass plates.

    LeProust E, Zhang H, Yu P, Zhou X, Gao X.
    Nucleic Acids Research. 2001 29(10) 2171-80
    Unexpected formation of parallel duplex in GAA and TTC trinucleotide repeats of Friedreich's ataxia.

    LeProust EM, Pearson CE, Sinden RR, Gao X.
    Journal of Molecular Biology. 2000 302(5) 1063-80
    Digital light-directed synthesis. A microarray platform that permits rapid reaction optimization on a combinatorial basis.

    LeProust E, Pellois JP, Yu P, Zhang H, Gao X, Srivannavit O, Gulari E, Zhou X.
    Journal of Combinatorial Chemistry. 2000 2(4) 349-54
  • Patrick Finn

    President and Chief Operating Officer

    Leer la biografía/publicaciones
    x

    Patrick Finn

    President and Chief Operating Officer

    Patrick tiene un sólido historial de ventas de alto crecimiento en organizaciones de fabricación personalizada, B2B y de biorreactivos. Su experiencia técnica, junto con su capacidad para identificar las necesidades no satisfechas del cliente, lo convierten en el candidato ideal para liderar nuestra organización comercial. Antes de Twist Bioscience, Paddy ejerció como vicepresidente de Ventas y Marketing de Enzymatics (recientemente adquirida por QIAGEN), y lideró las actividades comerciales para América del Norte y Europa, donde generó un crecimiento significativo en los ingresos y expandió la base de negocios a clientes empresariales. Antes de Enzymatics, Paddy ocupó cargos con un enfoque comercial cada vez mayor, incluido el de director de Desarrollo de Negocios en Agilent Technologies, director de Desarrollo de Productos de Beckman Coulter Molecular Diagnostics y múltiples funciones técnicas en el desarrollo de productos dentro de Invitrogen y GE Healthcare/Amersham International. Además, Paddy actualmente forma parte del Comité Asesor Científico de Lasergen y anteriormente formó parte del Comité Asesor Científico de Enzymatics. Tiene un doctorado en Química de Ácidos Nucleicos de la Universidad de Southampton y una licenciatura con honores en Química de la Universidad Heriot-Watt.

  • Adam Laponis

    DIRECTOR FINANCIERO

    Leer la biografía/publicaciones
    x

    Adam Laponis

    DIRECTOR FINANCIERO

    Adam has deep financial acumen and strategic planning expertise across diverse businesses along with a track record of collaborating across teams to drive profitable growth. Prior to joining Twist, Adam served as chief financial officer of Eargo, Inc., where he was responsible for finance, accounting, investor relations, business operations, internal audit and information technology. During his tenure at Eargo, revenue increased more than 300% over the course of two years. Prior to Eargo, Adam was vice president, worldwide financial planning and analysis and business operations at Tesla, Inc. where he was responsible for worldwide pricing, forecasting, capital planning, development of internal controls, and optimization of business operations. Previously, Adam served as vice president, finance and chief financial officer, cardiovascular care at Cardinal Health as the finance leader for the worldwide Cordis Cardiovascular business. He held a series of roles of increasing responsibility at Johnson & Johnson, where he led the divestiture of Cordis to Cardinal Health. He held additional positions within Johnson & Johnson including controller of the diabetes franchise, manager of supply chain and quality finance and customer service finance. Adam holds an MBA from the University of Southern California, Marshall School of Business and a B.S. in chemical engineering from the University of California at Berkeley.

  • Aaron Sato 博士

    Director científico

    Leer la biografía/publicaciones
    x

    Aaron Sato 博士

    Director científico

    Aaron es un líder en biología demostrado, experto en la gestión de equipos para descubrir y desarrollar nuevas terapias punteras de anticuerpos. Antes de Twist Bioscience, ejerció como director científico de LakePharma, dirigiendo el California Antibody Center, que descubre nuevas terapias con anticuerpos para sus clientes. Antes de LakePharma, supervisó todas las funciones de investigación de descubrimiento como vicepresidente de Ciencias de las Proteínas en Surrozen y, anteriormente, como vicepresidente de Investigación en Sutro Biopharma, Inc. También trabajó como director sénior de Ingeniería de Anticuerpos en OncoMed Pharmaceuticals, donde fue responsable del descubrimiento líder de anticuerpos humanos y como líder de equipo de proyecto en varios proyectos clave de anticuerpos a través de la presentación de nuevos fármacos en investigación. Antes de OncoMed, Aaron ocupó puestos de creciente responsabilidad en Dyax Corp., más recientemente como director sénior de Lead Discovery, líder en el descubrimiento de anticuerpos, péptidos y proteínas pequeñas utilizando su tecnología patentada de visualización de fagos. Obtuvo su doctorado en el Instituto de Tecnología de Massachusetts, donde estudió las relaciones estructura-función del CMH clase II. Es autor de más de 30 artículos revisados por especialistas y 40 patentes publicadas en el espacio de los anticuerpos.

    Publicaciones

     

    A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and Omicron.

    Tom Z. Yuan, Carolina Lucas, Valter S. Monteiro, Akiko Iwasaki, Marisa L. Yang, Hector F. Nepita, Ana G. Lujan Hernandez, Joseph M. Taft, Lester Frei, Sai T. Reddy, Cédric R. Weber, Kevin P. Malobisky, Rodrigo Mesquita, Aaron K. Sato. bioRxiv. 2022.01.04.474803; doi: https://doi.org/10.1101/2022.01.04.474803

    Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.

    Yuan TZ, Garg P, Wang L, Willis JR, Kwan E, Hernandez AGL, Tuscano E, Sever EN, Keane E, Soto C, Mucker EM, Fouch ME, Davidson E, Doranz BJ, Kailasan S, Aman MJ, Li H, Hooper JW, Saphire EO, Crowe JE, Liu Q, Axelrod F, Sato AK. MAbs. 2022 Jan-Dec;14(1):2002236. doi: 10.1080/19420862.2021.2002236. PMID: 34967699; PMCID: PMC8726723.

    Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study.

    Hastie KM, Li H, Bedinger D, Schendel SL, Dennison SM, Li K, Rayaprolu V, Yu X, Mann C, Zandonatti M, Diaz Avalos R, Zyla D, Buck T, Hui S, Shaffer K, Hariharan C, Yin J, Olmedillas E, Enriquez A, Parekh D, Abraha M, Feeney E, Horn GQ; CoVIC-DB team1, Aldon Y, Ali H, Aracic S, Cobb RR, Federman RS, Fernandez JM, Glanville J, Green R, Grigoryan G, Lujan Hernandez AG, Ho DD, Huang KA, Ingraham J, Jiang W, Kellam P, Kim C, Kim M, Kim HM, Kong C, Krebs SJ, Lan F, Lang G, Lee S, Leung CL, Liu J, Lu Y, MacCamy A, McGuire AT, Palser AL, Rabbitts TH, Rikhtegaran Tehrani Z, Sajadi MM, Sanders RW, Sato AK, Schweizer L, Seo J, Shen B, Snitselaar JJ, Stamatatos L, Tan Y, Tomic MT, van Gils MJ, Youssef S, Yu J, Yuan TZ, Zhang Q, Peters B, Tomaras GD, Germann T, Saphire EO.  Science. 23 de septiembre de 2021:eabh2315. doi: 10.1126/science.abh2315. Online ahead of print. PMID: 34554826

    Functional GLP-1R antibodies identified from a synthetic GPCR-focused library demonstrate potent blood glucose control.

    Liu Q, Garg P, Hasdemir B, Wang L, Tuscano E, Sever E, Keane E, Hernandez AGL, Yuan TZ, Kwan E, Lai J, Szot G, Paruthiyil S, Axelrod F, K Sato A. MAbs. 2021 Jan-Dec;13(1):1893425. doi: 10.1080/19420862.2021.1893425. PMID: 33706686; PMCID: PMC7971233.

    Rapid exploration of the epitope coverage produced by an Ebola survivor to guide the discovery of therapeutic antibody cocktails.

    Tom Z Yuan, Ana G Lujan Hernandez, Erica Keane, Qiang Liu, Fumiko Axelrod, Shweta Kailasan, Madeleine Noonan-Shueh, M Javad Aman, Aaron K Sato, Yasmina N Abdiche. Antib Ther. 1 de agosto de 2020: tbaa016. Published online 1 de agosto de 2020. doi: 10.1093/abt/tbaa016. PMCID: PMC7454256.

    Immunization with cell-free-generated vaccine protects from Porphyromonas gingivalis-induced alveolar bone loss.

    Huang N, Shimomura E, Yin G, Tran C, Sato A, Steiner A, Heibeck T, Tam M, Fairman J, Gibson FC 3rd. J Clin Periodontol. 2019 Feb;46(2):197-205. doi: 10.1111/jcpe.13047. Epub 2019 Jan PubMed PMID:30578564.

    26 de mayo; 10(6). pii: E286. doi: 10.3390/v10060286. PubMed PMID: 29861435.

    7 de mayo de 2018;15(5):2054-2059. doi: 10.1021/acs.molpharmaceut.8b00242. Epub 3 de marzo de 2018. PubMed PMID: 29569925.

    Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission.

    Kapoor N, Vanjak I, Rozzelle J, Berges A, Chan W, Yin G, Tran C, Sato AK, Steiner AR, Pham TP, Birkett AJ, Long CA, Fairman J, Miura K. Malaria Biochemistry. 6 de febrero de 2018;57(5):516-519. doi: 10.1021/acs.biochem.7b01099. Epub 16 de enero de 2018. PubMed PMID: 29323879; PubMed Central PMCID: PMC5803671.

    RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates.

    Yin G, Stephenson HT, Yang J, Li X, Armstrong SM, Heibeck TH, Tran C, Masikat MR, Zhou S, Stafford RL, Yam AY, Lee J, Steiner AR, Gill A, Penta K, Pollitt S, Baliga R, Murray CJ, Thanos CD, McEvoy LM, Sato AK, Hallam TJ. Sci Rep. 8 de junio de 2017;7(1):3026. doi:10.1038/s41598-017-03192-z. PubMed PMID: 28596531; PubMed Central PMCID: PMC5465077.

    RP-HPLC DAR Characterization of Site-Specific Antibody Drug Conjugates Produced in a Cell-Free Expression System.

    Xu Y, Jiang G, Tran C, Li X, Heibeck TH, Masikat MR, Cai Q, Steiner AR, Sato AK, Hallam TJ, Yin G. Org. Process Res. Dev., 2016, 20 (6): 1034–1043.

    Targeted Drug Delivery with an Integrin-Binding Knottin-Fc-MMAF Conjugate Produced by Cell-Free Protein Synthesis.

    Currier NV, Ackerman SE, Kintzing JR, Chen R, Filsinger Interrante M, Steiner A, Sato AK, Cochran JR. Mol Cancer Ther. 2016 Jun;15(6):1291-300. doi: 10.1158/1535-7163.MCT-15-0881. Epub 29 de marzo de 2016. PubMed PMID: 27197305.

    Targeting notch signaling with a notch2/notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.

    Yen WC, Fischer MM, Axelrod F, Bond C, Cain J, Cancilla B, Henner WR, Meisner  R, Sato A, Shah J, Tang T, Wallace B, Wang M, Zhang C, Kapoun AM, Lewicki J, Gurney A, Hoey T. Clin Cancer Res. 1 de mayo de 2015;21(9):2084-95. doi: 10.1158/1078-0432.CCR-14-2808. PubMed PMID: 25934888.

    A simplified and robust protocol for immunoglobulin expression in Escherichia coli cell-free protein synthesis systems.

    Cai Q, Hanson JA, Steiner AR, Tran C, Masikat MR, Chen R, Zawada JF, Sato AK, Hallam TJ, Yin G. Biotechnol Prog. 2015 May-Jun;31(3):823-31. doi: 10.1002/btpr.2082. Epub 18 de abril de 2015.PubMed PMID: 25826247.

    Methods to Make Homogenous Antibody Drug Conjugates.

    Kline T, Steiner AR, Penta K, Sato AK, Hallam TJ, Yin G. Pharm Res. 2015 Nov;32(11):3480-93. doi:10.1007/s11095-014-1596-8. Epub 16 de diciembre de 2014. PubMed PMID: 25511917; PubMed Central PMCID: PMC4596908.

    Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system.

    Xu Y, Lee J, Tran C, Heibeck TH, Wang WD, Yang J, Stafford RL, Steiner AR, Sato AK, Hallam TJ, Yin G. MAbs. 2015;7(1):231-42. doi: 10.4161/19420862.2015.989013. PubMed PMID: 25427258; PubMed Central PMCID: PMC4623329.

    A general sequence processing and analysis program for protein engineering.

    Stafford RL, Zimmerman ES, Hallam TJ, Sato AK. J Chem Inf Model. 27 de octubre de 2014;54(10):3020-32. doi: 10.1021/ci500362s. Epub 3 de octubre de 2014. PubMed PMID: 25243907.

    In vitro Fab display: a cell-free system for IgG discovery.

    Stafford RL, Matsumoto ML, Yin G, Cai Q, Fung JJ, Stephenson H, Gill A, You M, Lin SH, Wang WD, Masikat MR, Li X, Penta K, Steiner AR, Baliga R, Murray CJ, Thanos CD, Hallam TJ, Sato AK. Protein Eng Des Sel. 2014 Apr;27(4):97-109. doi: 10.1093/protein/gzu002. Epub 28 de febrero de 2014. PubMed PMID: 24586053; PubMed Central PMCID: PMC3966677.

    Engineering toward a bacterial "endoplasmic reticulum" for the rapid expression of immunoglobulin proteins.

    Groff D, Armstrong S, Rivers PJ, Zhang J, Yang J, Green E, Rozzelle J, Liang S, Kittle JD Jr, Steiner AR, Baliga R, Thanos CD, Hallam TJ, Sato AK, Yam AY. MAbs. 2014 May-Jun;6(3):671-8. doi: 10.4161/mabs.28172. Epub 11 de febrero de 2014. PubMed PMID: 24517929; PubMed Central PMCID: PMC4011911.

    Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system.

    Zimmerman ES, Heibeck TH, Gill A, Li X, Murray CJ, Madlansacay MR, Tran C, Uter NT, Yin G, Rivers PJ, Yam AY, Wang WD, Steiner AR, Bajad SU, Penta K, Yang W, Hallam TJ, Thanos CD, Sato AK. Bioconjug Chem. 19 de febrero de 2014;25(2):351-61. doi: 10.1021/bc400490z. Epub 29 de enero de 2014. PubMed PMID: 24437342.

    Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.

    Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, Lam A, Lazetic S, Ma S, Mitra S, Park IK, Pickell K, Sato A, Satyal S, Stroud M, Tran H, Yen WC, Lewicki J, Hoey T. Proc Natl Acad Sci U S A. 17 de julio de 2012;109(29):11717-22. doi: 10.1073/pnas.1120068109. Epub 2 de julio de 2012. PubMed PMID:  22753465; PubMed Central PMCID: PMC3406803.

    DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.

    Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A, Satyal S, Wang X, Clarke MF, Lewicki J, Gurney A. Cell Stem Cell. 7 de agosto de 2009;5(2):168-77. doi: 10.1016/j.stem.2009.05.019. PubMed PMID: 19664991.

    Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.

    van der Horst EH, Chinn L, Wang M, Velilla T, Tran H, Madrona Y, Lam A, Ji M,  Hoey TC, Sato AK. Neoplasia. 2009 Apr;11(4):355-64. PubMed PMID: 19308290; PubMed Central PMCID: PMC2657888.

    Development of an Antibody Screening Assay for Selection of Production Cell Lines. Idusogie E. E., Castro J.M., Casipit C., Sato A.,Terasawa Y., and Mulkerrin M.G. Bioprocess Int. 2008 April: 20-33.

    Identification of an ADAMTS-4 cleavage motif using phage display leads to the development of fluorogenic peptide substrates and reveals matrilin-3 as a novel substrate.

    Hills R, Mazzarella R, Fok K, Liu M, Nemirovskiy O, Leone J, Zack MD, Arner EC, Viswanathan M, Abujoub A, Muruganandam A, Sexton DJ, Bassill GJ, Sato AK, Malfait AM, Tortorella MD. J Biol Chem. 13 de abril de 2007;282(15):11101-9. Epub 20 de febrero de 2007. PubMed PMID: 17311924.

    Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol.

    Sato AK, Viswanathan M, Kent RB, Wood CR. 2006 Dec;17(6):638-42. Epub 17 de octubre de 2006. Review. PubMed PMID: 17049837.

    Discovery of human antibodies against the C5aR target using phage display technology.

    Huang L, Sato AK, Sachdeva M, Fleming T, Townsend S, Dransfield DT. J Mol Recognit. 2005 Jul-Aug;18(4):327-33. PubMed PMID: 15706605.

    Phage display-derived peptides as therapeutic alternatives to antibodies.

    Ladner RC, Sato AK, Gorzelany J, de Souza M. Drug Discov Today. 15 de junio de 2004;9(12):525-9. Review. PubMed PMID: 15183160.

    Sato A.K. Use of peptide phage display in therapeutics, diagnostics, and affinity separations. Biopolymers. 2003 71(3) 316.

    Development of mammalian serum albumin affinity purification media by peptide phage display.

    Sato AK, Sexton DJ, Morganelli LA, Cohen EH, Wu QL, Conley GP, Streltsova Z,  Lee SW, Devlin M, DeOliveira DB, Enright J, Kent RB, Wescott CR, Ransohoff TC, Ley AC, Ladner RC. Biotechnol Prog. 2002 Mar-Apr;18(2):182-92. PubMed PMID: 11934284.

    Nitriles form mixed-coligand complexes with (99m)Tc-HYNIC-peptide.

    Liu G, Wescott C, Sato A, Wang Y, Liu N, Zhang YM, Rusckowski M, Hnatowich DJ. Nucl Med Biol. 2002 Jan;29(1):107-13. PubMed PMID: 11786281.

    Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1.

    Sato AK, Zarutskie JA, Rushe MM, Lomakin A, Natarajan SK, Sadegh-Nasseri S, Benedek GB, Stern LJ. J Biol Chem. 21 de enero de 2000;275(3):2165-73. PubMed PMID: 10636922.

    Substitution of aspartic acid at beta57 with alanine alters MHC class II peptide binding activity but not protein stability: HLA-DQ (alpha1*0201, beta1*0302)和(alpha1*0201, beta1*0303)。Hum Immunol.

    Sato AK, Sturniolo T, Sinigaglia F, Stern LJ. 1999 Dec;60(12):1227-36. PubMed PMID: 10626736.

    Extracellular antigen processing and presentation by immature dendritic cells.

    Santambrogio L, Sato AK, Carven GJ, Belyanskaya SL, Strominger JL, Stern LJ. Proc Natl Acad Sci U S A. 21 de diciembre de 1999;96(26):15056-61. PubMed PMID: 10611337; PubMed Central PMCID: PMC24772.

    Abundant empty class II MHC molecules on the surface of immature dendritic cells.

    Santambrogio L, Sato AK, Fischer FR, Dorf ME, Stern LJ. Proc Natl Acad Sci U S A. 21 de diciembre de 1999;96(26):15050-5. PubMed PMID: 10611336; PubMed Central PMCID: PMC24771.

    A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding.

    Zarutskie JA, Sato AK, Rushe MM, Chan IC, Lomakin A, Benedek GB, Stern LJ. Biochemistry. 4 de mayo de 1999;38(18):5878-87. PubMed PMID: 10231540.

    Empty and peptide-loaded class II major histocompatibility complex proteins produced by expression in Escherichia coli and folding in vitro.

    Frayser M, Sato AK, Xu L, Stern LJ. Protein Expr Purif. 1999 Feb;15(1):105-14. PubMed PMID: 10024477.

    Steady-state and time-resolved phosphorescence of 5-hydroxy-L-tryptophan l cI repressor bound to DNA.

    Sato, A.K., Bitten E.R., Lambert D., and Rousslang K.W. SPIE Proceedings 1994 2137 343-351.

    Steady-state and time-resolved phosphorescence of wild-type and modified bacteriophage λcI repressors.

    Sato AK, Bitten ER, Senear DF, Alexander Ross JB, Rousslang KW.J Fluoresc. 1994 Jun;4(2):195-201. doi: 10.1007/BF01881888. PubMed PMID: 24233382.

  • 陈思远
    陈思远

    Director de Tecnología

    Leer la biografía/publicaciones
    x
    陈思远

    陈思远

    Director de Tecnología

    El Dr. Chen es un pensador estratégico con un historial comprobado de identificación, desarrollo y comercialización de productos innovadores en secuenciación de última generación (NGS), biología sintética y otras áreas de la biociencia. Se incorporó a Twist poco después de la fundación de la empresa y lideró el desarrollo de productos para las líneas de productos de biología sintética y secuenciación de última generación (NGS). El Dr. Chen concibió e implementó una nueva línea de productos para secuenciación de última generación (NGS) que incluye controles sintéticos para el SARS-CoV-2 y otras enfermedades infecciosas, desarrolló síntesis de genes y bioquímicas de enriquecimiento del objetivo por NGS, flujos de trabajo, kits de reactivos, e infraestructuras, y construyó el prototipo de sintetizador de ADN de la empresa en colaboración con ingenieros de hardware, software e informáticos, que luego se convirtió en una máquina a escala de producción y sirvió como la tecnología base de Twist. El Dr. Chen es autor de numerosos artículos revisados por especialistas y patentes publicadas en el campo de la síntesis de oligonucleótidos y la aplicación de oligonucleótidos sintéticos. Obtuvo su doctorado en Química en la Universidad de Wisconsin (Madison) y su licenciatura en Química en la Universidad de Pekín (China), 

  • Paula Green

    Vicepresidenta sénior de Recursos Humanos

    Leer la biografía/publicaciones
    x

    Paula Green

    Vicepresidenta sénior de Recursos Humanos

    Paula Green es una ejecutiva de recursos humanos con experiencia y con un historial de desarrollo y presentación de estrategias, soluciones, procesos y herramientas de alto impacto para las personas que respalda las competencias de liderazgo para impulsar una organización de alto rendimiento. Antes de Twist Bioscience, ejerció como vicepresidenta, jefa de Recursos Humanos en QIAGEN, donde supervisó a 50 profesionales de recursos humanos que asistían a 4000 empleados en fusiones y adquisiciones, reestructuraciones y otras transacciones corporativas fundamentales. Fue la gerente de recursos humanos de Operon Technologies (adquirida por QIAGEN), donde sus responsabilidades incluían la creación de estrategias, la supervisión de los beneficios para todos los empleados y el suministro de programas de capacitación, reclutamiento y retención. También trabajó como consultora de recursos humanos para el Federal Home Loan Bank de San Francisco. Paula tiene una licenciatura en Comportamiento Organizacional de la Universidad de San Francisco. 

  • Chet Gandhi

    Chief Information Officer

    Leer la biografía/publicaciones
    x

    Chet Gandhi

    Chief Information Officer

    Chet’s areas of expertise include cloud computing, application and solution architecture, cybersecurity, artificial intelligence and data analytics. Prior to joining Twist, Chet served as chief information officer at Wineshipping, where he successfully led the company’s transformation from logistics to a technology-driven organization, optimizing the technology stack, enhancing the consumer experience, and driving internal efficiency. Previously, he held key leadership positions including vice president and global head of IT at Intapp and chief information officer and head of technology at Magento Commerce (acquired by Adobe). He also held a series of progressively responsible roles at Applied Micro Circuits. Chet holds a master’s of applied science in engineering from the University of British Columbia and a bachelor’s in technology from the Indian Institute of Technology.

  • Mark Buck

    Senior Vice President of Operations

    Leer la biografía/publicaciones
    x

    Mark Buck

    Senior Vice President of Operations

    Mark is experienced in improving manufacturing efficiency and driving revenue and margin through managing supply chain and operations, including planning, quality, procurement and logistics. Prior to joining Twist, Mark served as corporate senior vice president, operations, global supply chain at Excelitas Technologies Corporation where he established a global footprint, drove global supply chain optimization measures, enabled scale up and drove revenue growth. His responsibilities included global supply chain planning, global sourcing and procurement supply, internal supply, supply quality and logistics inbound and outbound movement of freight. Prior to Excelitas, Mark was director, global supply chain management and general manager of resale product operations at Bio-Rad, Inc., where he managed buy-sell products, which grew in revenue to $270 million, significantly improving profitability over his time in the role. He previously held leadership positions including vice president operations, global manufacturing, supply chain and logistics at Celerity Group; director, operations management at Solectron corporation; and senior supply chain operations manager at Apple Computer, Inc. Before joining industry, Mark served in the United States Marine Corps. He holds an MBA from National University and a B.S. in electrical and computer engineering from University of Illinois, Urbana-Champaign.

  • Dr. Bill Banyai

    Vicepresidente sénior de Desarrollo Avanzado y director general de Almacenamiento de Datos

    Leer la biografía/publicaciones
    x

    Dr. Bill Banyai

    Vicepresidente sénior de Desarrollo Avanzado y director general de Almacenamiento de Datos

    Bill es un empresario experimentado y experto en ingeniería informática. Fue fundador o primer empleado de cuatro empresas emergentes diferentes y asesora a empresas emergentes en sus etapas iniciales. Como vicepresidente de Ingeniería de Hardware en Complete Genomics, desarrolló su tecnología de secuenciación y creó tres generaciones de chips y secuenciadores del genoma humano. Bill ha recibido dos subvenciones DARPA multimillonarias para el desarrollo de tecnologías innovadoras basadas en el micromecanizado computarizado. La carrera de Bill abarca la investigación, el desarrollo de productos y el procesamiento de dispositivos semiconductores. Tiene un doctorado en Ciencias Ópticas de la Universidad de Arizona, un grado en Ciencias Eléctricas de la Universidad de Michigan y ejerció como físico de plantilla en el Laboratorio Nacional Lawrence Livermore.

    Publicaciones
    Human Genome Sequencing Using Unchained Base Reads on Self-Assembling DNA Nanoarrays.

    Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, Kermani BG, Carnevali P, Nazarenko I, Nilsen GB, Yeung G, Dahl F, Fernandez A, Staker B, Pant KP, Baccash J, Borcherding AP, Brownley A, Cedeno R, Chen L, Chernikoff D, Cheung A, Chirita R, Curson B, Ebert JC, Hacker CR, Hartlage R, Hauser B, Huang S, Jiang Y, Karpinchyk V, Koenig M, Kong C, Landers T, Le C, Liu J, McBride CE, Morenzoni M, Morey RE, Mutch K, Perazich H, Perry K, Peters BA, Peterson J, Pethiyagoda CL, Pothuraju K, Richter C, Rosenbaum AM, Roy S, Shafto J, Sharanhovich U, Shannon KW, Sheppy CG, Sun M, Thakuria JV, Tran A, Vu D, Zaranek AW, Wu X, Drmanac S, Oliphant AR, Banyai WC, Martin B, Ballinger DG, Church GM, Reid CA.
    Science. 2010 327(5961) 78-81
    Modular MEMS design and fabrication for an 80 x 80 transparent optical cross-connect switch.

    Fernandez A, Staker BP, Owens WE, Muray LP, Spallas JP, Banyai WC.
    Proceedings SPIE - Optomechatronic Micro/Nano Components, Devices, and Systems. 2004 5604 208-217
    Scaling behavior in interference lithography.

    Agayan RR, Banyai WC, Fernandez AJ.
    Proceedings SPIE - Emerging Lithographic Technologies II. 1998 3331 662-672
    Time-to-frequency converter for measuring picosecond optical pulses.

    Kauffman MT, Banyai WC, Godil AA, Bloom DM.
    Applied Physics Letters. 1994 64(3) 270-272
    Applications of time lens optical systems.

    Kauffman MT, Godil AA, Auld BA, Banyai WC, Bloom DM.
    Electronics Letters. 1993 29(3) 268-269
    Interaction of super-intense light fields with atoms and surfaces.

    Downer MC, Banyai WC, Wood WM, Anacker DC, Erskine JL.
    Proceedings SPIE - Picosecond and Femtosecond Spectroscopy from Laboratory to Real World. 1990 1209 166-174
    Spectral shifting of femtosecond pulses in atmospheric density plasmas.

    Spectral shifting of femtosecond pulses in atmospheric density plasmas.
     
    Picosecond pump-probe interferometric measurement of optical nonlinearities in channel waveguides.

    Finlayson N, Banyai WC, Seaton CT, Stegeman GI, O'Neill M, Cullen TJ, Ironside CN.
    Optics Letters. 1989 14(10) 532-534
    Optical nonlinearities in CdSxSe1-x-doped glass waveguides.

    Finlayson N, Banyai WC, Seaton CT, Stegeman GI, O'Neill M, Cullen TJ, Ironside CN.
    Journal of the Optical Society of America B: Optical Physics. 1989 6(4) 675-684
    Saturation of the nonlinear refractive-index change in a semiconductor-doped glass channel waveguide.

    Banyai WC, Finlayson N, Seaton CT, Stegeman GI, O’Neill M, Cullen TJ, Ironside CN.
    Applied Physics Letters. 1989 54(6) 481-483
    Observation of ultrafast nonlinear polarization switching induced by polarization instability in a birefringent fiber rocking filter.

    Trillo S, Wabnitz S, Banyai WC, Finlayson N, Seaton CT, Stegeman GI, Stolen RH.
    IEEE Journal of Quantum Electronics. 1989 25(1) 104-112
    Picosecond switching induced by saturable absorption in a nonlinear directional coupler.

    Finlayson N, Banyai WC, Wright EM, Seaton CT., Stegeman GI, Cullen TJ, Ironside CN.
    Applied Physics Letters. 1988 53(13) 1144-1146
    Picosecond nonlinear polarization switching with a fiber filter.

    Trillo S, Wabnitz S, Finlayson N, Banyai WC, Seaton CT, Stegeman GI, Stolen RH.
    Applied Physics Letters. 1988 53(10) 837-839
    Nonlinear-optical effects in ion-exchanged semiconductor-doped glass waveguides.

    Ironside CN, Cullen TJ, Bhumbra BS, Bell JA, Banyai WC, Finlayson N, Seaton CT, Stegeman GI.
    Journal of the Optical Society of America B: Optical Physics. 1988 5(2) 492-495
    High-speed intensity-dependent refractive index in semiconductor-doped glasses.

    Seaton CT, Stegeman GI, Yao SS, Karaguleff C, Fortenberry R, Gabel A, Banyai W, Assanto G.
    Proceedings SPIE - Advances in Materials for Active Optics. 1985 567 132
  • Tracey Mullen, MBA

    Senior Vice President of Biopharma

    Leer la biografía/publicaciones
    x

    Tracey Mullen, MBA

    Senior Vice President of Biopharma

    Tracey joined Twist in December 2021 through the acquisition of Abveris, a company offering premium in vivo antibody drug discovery services, in November 2021. Prior to Twist, she served as CEO of Abveris. Tracey initially served as Abveris’ chief operating officer where she managed operations and project development for both therapeutic and critical reagent in vivo antibody discovery campaigns. Before Abveris, she served on the antibody discovery team at Biogen where she helped implement the technology transfer of the Adimab yeast display platform for antibody discovery and engineering. Throughout her tenure at Biogen, Tracey worked to optimize the in vitro discovery of antibodies to traditionally difficult therapeutic targets, including leveraging the Adimab platform to generate antibodies against GPCRs. Previously she worked for a contract research organization specializing in in vivo antibody. She received her B.S. in Chemical and Biological Engineering from the Massachusetts Institute of Technology and her Executive MBA from Quantic School of Business and Technology.

  • Nimisha Srivastava, Ph.D.

    Senior Vice President of R&D

    Leer la biografía/publicaciones
    x

    Nimisha Srivastava, Ph.D.

    Senior Vice President of R&D

    Nimisha joined Twist in March 2014 and was instrumental in automating processes and procedures to fuel the growth of Twist into a leading global manufacturer of synthetic DNA. She built out the core technology team and scaled up key laboratory processes, workflows and automation, which enabled the high-throughput production of novel synthetic DNA-based offerings. Prior to joining Twist, Nimisha held key technical and leadership positions at various startups as well as academic and national laboratories where she drove the development and scale up of microfluidics technologies for multiplexed pathogen detection and in vitro diagnostics. She holds a B.S. in chemical engineering from the Indian Institute of Technology, New Delhi and an M.S. and Ph.D. in chemical engineering from the University of Michigan, Ann Arbor where she studied the intersection of genetics, miniaturization, and dynamics of complex fluids.

    Publicaciones

    Srivastava N., Brennan J.S., Renzi R.F., Wu M., Branda S.S, Singh A.K, and Herr A.E, (2009), ‘Fully Integrated Microfluidic Platform Enabling Automated Phosphoprofiling of Macrophage Response’, Analytical Chemistry

    Srivastava N., Changsong D., Judson A., McDonald N., and Meinhart C.D. (2010), ‘A unified scaling model for flow through a lattice of microfabricated posts’, Lab on a Chip, DOI:10.1039/B919942J

    Srivastava N., Burns M.A. ‘Electronic Drop Sensing In Microfluidic Devices: Automated Operation of a Nanoliter Viscometer’ Lab On A Chip 6: 744 -751(2006)

    Srivastava N., Burns M.A. ‘Analysis of non-Newtonian Liquids using a microfluidic capillary viscometer’ Analytical Chemistry 78: 6890-6896 (2006)

    Srivastava N., Davenport R.D., Burns M.A. ‘A Nanoliter Viscometer for analyzing blood plasma and other liquid samples’ Analytical Chemistry 77(2): 383-392, 2005

    Pal R., Yang M., Lin R., Johnson B.N., Srivastava N., Razzacki Z., et al ‘An integrated microfluidic device for 
    influenza and other genetic analyses’. Lab on A Chip, Cover Page, 5(10), 1024, 2005

    Srivastava N., Roy A., Pant N., Bhaskarwar A.N. ‘Washing Kinetics of a novel pollution preventing ink’ Chemical Engineering Science 60: 1725-1731, 2005

    Research Highlight ‘Nanolitre Viscometer’ in Lab Chip 5: 370-373, 2005
     

  • Director de ASG, vicepresidente principal de Asuntos Corporativos
    Angela Bitting

    Director de ASG, vicepresidente principal de Asuntos Corporativos

    Leer la biografía/publicaciones
    x
    Director de ASG, vicepresidente principal de Asuntos Corporativos

    Angela Bitting

    Director de ASG, vicepresidente principal de Asuntos Corporativos

    Como ejecutiva sénior de comunicaciones con más de veinticinco años de experiencia en el sector biofarmacéutico, Angela sobresale con mensajes nítidos y comunicaciones coherentes, lo que aumenta la visibilidad entre las principales partes interesadas, además de llevar la cultura y la comunicación a toda la organización. Antes de Twist, dirigió su propia oficina de consultoría durante 20 años y trabajó con clientes biofarmacéuticos, de productos sanitarios y de diagnóstico para crear mensajes clave con el fin de implementar una comunicación efectiva entre audiencias externas. Antes de comenzar su propia consultoría, Angela dirigió el departamento de Relaciones con Inversores y Comunicaciones Corporativas de Exelixis, Inc. Pasó varios años en Russell-Welsh, Inc., una agencia boutique de comunicaciones sanitarias, y trabajó con una gran variedad de clientes públicos y privados en una amplia gama de servicios de comunicaciones. Posee una licenciatura en Biología Celular y Molecular y otra en Marketing Empresarial, ambas de la Universidad de Washington. Actualmente ejerce como vicepresidenta provisional de su división local de la Liga de Caridad Nacional.

  • Dennis Cho

    Chief Legal Officer and Corporate Secretary

    Leer la biografía/publicaciones
    x

    Dennis Cho

    Chief Legal Officer and Corporate Secretary

    Dennis Cho is a seasoned in-house business attorney with a proven track record of agile strategic guidance and practical problem solving. Prior to Twist, he served as assistant general counsel at CytomX Therapeutics, where he was department head for all deals and contracts as well as day-to-day lead on compliance and numerous other legal subject matters. Prior to CytomX, Mr. Cho was the lead transactional attorney on antibody-related licenses and collaborations, major commercial agreements, and combination trials at Seattle Genetics. Before that, he spent nine years at Celgene as the lead West Coast attorney supervising over 100 business transactions, including in- and out- licenses, options, collaborations and M&A agreements, and held primary legal responsibility for Celgene’s alliances, equity investments and “big data” machine learning initiative. Prior to Celgene, Mr. Cho served as general counsel for four private and public companies. He earned his J.D. and a B.A. in Molecular Cell Biology (Genetics) from University of California, Berkeley.

Equipo

Junta

Rob Chess

Presidente del consejo de directores
Nektar Therapeutics

Nelson C. Chan

Presidente del consejo
Synaptics 和 Adesto

Keith Crandell

Cofundador y director gerente
Arch Venture Partners

Jan Johannessen

Asesor de iGlobe Partners

Xiaoying Mai

Head of Private Equity, GF Investments (Hong Kong) Company Limited

Bob Ragusa

CEO
GRAIL, LLC

Melissa Starovasnik, Ph.D.

Former Vice President, Protein Sciences and Head of Large Molecule Drug Discovery
Genentech

Emily Leproust

Directora ejecutiva
Twist Bioscience

Tenga una influencia positiva.

Ver todas las vacantes disponibles
Powered by Translations.com GlobalLink OneLink Software
Powered by Translations.com GlobalLink OneLink Software